Vincent Escuyer
Biographic Data
| ID | 9993934 |
|---|---|
| NAME | Vincent Escuyer |
| GIVEN NAMES | Vincent |
| FAMILY NAME | Escuyer |
| SIGNATURE | ESCUYER V |
| AFFILIATIONS | New York State Department of Health |
| ORCID | 0000-0002-4435-6709 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2012 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Direct detection of drug-resistant Mycobacterium tuberculosis using targeted next generation sequencing
Mycobacterium tuberculosis complex (MTBC) infections are treated with combinations of antibiotics; however, these regimens are not as efficacious against multidrug and extensively drug resistant MTBC. Phenotypic (growth-based) drug susceptibility testing on slow growing bacteria like MTBC requires many weeks to months to complete, whereas sequencing-based approaches can predict drug resistance (DR) with reduced turnaround time. We sought to devel…
Multidrug-resistant tuberculosis in Port-au-Prince, Haiti
This study shows an MDR-TB prevalence of 2.9% in newly diagnosed TB patients in Haiti and suggests that rpoB sequencing and hybridization assays are good screening tools for early detection of MDR-TB
No prominent works on this page.
Multidrug-resistant tuberculosis in Port-au-Prince, Haiti
This study shows an MDR-TB prevalence of 2.9% in newly diagnosed TB patients in Haiti and suggests that rpoB sequencing and hybridization assays are good screening tools for early detection of MDR-TB
Direct detection of drug-resistant Mycobacterium tuberculosis using targeted next generation sequencing
Mycobacterium tuberculosis complex (MTBC) infections are treated with combinations of antibiotics; however, these regimens are not as efficacious against multidrug and extensively drug resistant MTBC. Phenotypic (growth-based) drug susceptibility testing on slow growing bacteria like MTBC requires many weeks to months to complete, whereas sequencing-based approaches can predict drug resistance (DR) with reduced turnaround time. We sought to devel…
Biology (2 works) · Drug resistance (2 works) · Medicine (2 works) · Microbiology (2 works) · Pathology (2 works) · Tuberculosis (2 works) · Tuberculosis Research and Epidemiology (2 works) · Amplicon (1 work) · Antibiotic Resistance in Bacteria (1 work) · Electrical engineering (1 work)